Phillip M. Satow is Chairman of the Board of Directors at Nutrition 21. Phillip comes to Nutrition 21 with more than 30 years of experience in the pharmaceutical industry. He was Co-founder, Chairman and CEO of JDS Pharmaceuticals, a specialty pharmaceutical company focused on the psychiatry and women’s health markets. Phillip and his son, Michael, grew JDS to more than $30 million in sales in three years, before selling the company to Noven Pharmaceuticals in 2007 for $125 million.

Prior to founding JDS, Phillip served as Executive Vice President of Forest Laboratories, where he oversaw all marketing and sales functions. He also held the position of President of Forest Pharmaceuticals and was a former member of the Forest Board of Directors. At Forest, Phillip built the company’s sales and marketing infrastructure and retired after launching Forest’s first $1 billion product – the anti-depressant Celexa. Prior to joining Forest, he served as Vice President and General Manager of the Wallace Laboratories Division of Carter–Wallace. In addition, he has held a variety of executive positions at Pfizer, including Director of Marketing of Pfizer Laboratories and Vice President of Pfizer Europe. Phillip has also served on the boards of directors of Crucell, Eyetech and Noven, as well as various others.

Phillip received a BA from Columbia College and an MA from Georgetown University.